Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine

Pediatr Hematol Oncol. Jul-Aug 2005;22(5):441-5. doi: 10.1080/08880010590964381.

Abstract

Cisplatin in higher doses have been used routinely in the treatment of childhood tumours including neuroblastoma and germ cell tumors. Amifostine, a broad-spectrum cytoprotector of normal tissues, has been approved by U.S. Food and Drug Administration for use in patients receiving cisplatin. Such administration of amifostine has been reported to reduce cisplatin-related toxicities in some studies, but not all. The authors report a case of severe toxicity with cisplatin in a girl with epithelial cell carcinoma of the ovary despite the use of amifostine.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Amifostine / administration & dosage
  • Amifostine / adverse effects*
  • Amifostine / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma / drug therapy*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects*
  • Cisplatin / therapeutic use
  • Drug Administration Schedule
  • Fatal Outcome
  • Female
  • Hearing / drug effects*
  • Humans
  • Injections, Intravenous
  • Kidney / drug effects*
  • Nervous System / drug effects*
  • Ovarian Neoplasms / drug therapy*
  • Recurrence
  • Treatment Outcome

Substances

  • Amifostine
  • Cisplatin